SciBase Nevisense Study Published
Analysis based on 6 articles · First reported Jun 09, 2026 · Last updated Jun 09, 2026
The publication of this study is expected to positively impact SciBase Holding AB's stock price due to increased validation and potential for broader adoption of its Nevisense technology. It could also attract further investment in the medical technology sector focused on dermatology and early disease detection.
SciBase Holding AB announced the publication of a study in the peer-reviewed journal Allergy, demonstrating that its Nevisense device can identify children at risk of developing atopic dermatitis shortly after birth. The study, conducted by researchers at the Icahn School of Medicine at Mount Sinai, found that infants who developed atopic dermatitis had significantly higher neonatal Nevisense measurements. This suggests Nevisense can serve as a non-invasive early biomarker for skin barrier dysfunction, enabling earlier risk assessment and supporting future prevention strategies for atopic dermatitis, a common chronic inflammatory skin disease affecting 15-20% of children worldwide.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard